Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for meta- static colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254-62.
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-66.
Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009;115:752-9.
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9.
Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007;14:786-94.
Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984;199:502-8.
Dhir M, Lyden ER, Wang A, et al. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg 2011;254:234-42.
Muratore A, Ribero D, Zimmitti G, et al. Resection margin and recurrence-free survival after liver resec- tion of colorectal metastases. Ann Surg Oncol 2010;17:1324-9.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recur- rence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-22.
Arru M, Aldrighetti L, Castoldi R, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 2008;32:93-103.
Vandeweyer D, Neo EL, Chen JW, et al. Influence of resection margin on survival in hepatic resections for colorectal liver metastases. HPB (Oxford) 2009;11:499-504.
Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) 2010;12:227-38.
Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg 1988;155:378-82.
Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986;100:278-84.
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
Bozzetti F, Doci R, Bignami P, et al. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg 1987;205:264-70.
Topal B, Kaufman L, Aerts R, et al. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 2003;29:248-53.
Metcalfe M, Mann C, Mullin E, et al. Detecting curable disease following hepatectomy for colorectal metastases. ANZ J Surg 2005;75:524-7.
Ueno H, Mochizuki H, Hashiguchi Y, et al. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 2004;91:327-33.
Mutsaerts EL, van Ruth S, Zoetmulder FA, et al. Prog- nostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 2005;9: 178-86.
Takahashi S, Inoue K, Konishi M, et al. Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases. Surgery 2003; 133:627-34.
Chua TC, Saxena A, Chu F, et al. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol 2011;103:796-800.
Bhattacharjya S, Aggarwal R, Davidson BR. Intensive follow-up after liver resection for colorectal liver metas- tases: results of combined serial tumour marker estima- tions and computed tomography of the chest and abdomen - a prospective study. Br J Cancer 2006;95:21-6.
Yamada H, Katoh H, Kondo S, et al. Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology 2001;48:828-30.
Nishio H, Hamady ZZ, Malik HZ, et al. Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol 2007;33:729-34.
de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009;13: 2141-51.
Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13: 1261-8.
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006; 20:1161-76.
Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy- -an intergroup study. J Clin Oncol 2002;20:1499-505.
Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975-9.
Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008;26:3672-80.
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53.
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9.
ismuth H, Adam R, Levi F, et al. Resection of nonre- sectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20.
rdlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16.
Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75.
Van Cutsem E, Verslype C, Beale P, et al. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 2008;19:332-9.
Falcone A, Masi G, Loupakis F, et al. FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group. J Clin Oncol 2008;26:abstr 4031.
Garufi C, Torsello A, Tumolo S, et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/ leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 2009;27:abstr e15020.
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
Wu YZ, Li B, Wang T, et al. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol 2011;17:4143-8.
Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 2011;13:e252-65.
Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resect- able colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012.
Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer 2003;97:3027-35.
Rivoire M, De Cian F, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95:2283-92.
Coster HG. A quantitative analysis of the voltagecurrent relationships of fixed charge membranes and the associated property of “punch-through”. Biophys J 1965;5:669-86.
Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol 1972;10:279-90.
Crowley JM. Electrical breakdown of bimolecular lipid membranes as an electromechanical instability. Biophys J 1973;13:711-24.
Zimmermann U, Pilwat G, Riemann F. Dielectric breakdown of cell membranes. Biophys J 1974;14:881-99.
Rubinsky B, Onik G, Mikus P. Irreversible electro- poration: a new ablation modality--clinical implications. Technol Cancer Res Treat 2007;6:37-48.
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33:223-31.
Edd JF, Horowitz L, Davalos RV, et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53: 1409-15.